Prazosin (1 mg, 2 mg, 5 mg): Supply issue

Supply issue Active

Due to a fire at a manufacturing plant, there is a supply issue affecting all strengths of prazosin.

Affected products

A fire has closed the manufacturing plant for the active ingredient in prazosin tablets. This has led to supply issue affecting prazosin tablets. 

The Arrotex brand of prazosin tablets was funded as an unapproved product in November 2021 following the withdrawal of the registered supplier from New Zealand.

Chemical: Prazosin

Brand: Arrotex-Prazosin S29

Schedule listing for prazosin(external link)

  • Presentation: Tab 1 mg
  • Pharmacode: 2625725
  • Stock status: Stock expected to last until February 2024
  • Presentation: Tab 2 mg
  • Pharmacode: 2625733
  • Stock status: Stock expected to last until February 2024 
  • Presentation: Tab 5 mg
  • Pharmacode: 2625741
  • Stock status: Out of stock with the supplier - some stock will be in the supply chain.

Temporary listing

We have sourced 2 to 3 months' supply of the Minipress s29 brand of prazosin tablets. 

Minipress prazosin can't be supplied long term. It is providing additional supply while we continue to explore options for on-going supply.

From 23 January 2024, 1 mg, 2 mg and 5 mg tablets of Minipress s29 will be listed. They will be listed as section 29. This is the same as the Arrotex-Prazosin brand. Wastage applies.

  • 1 mg | Pharmacode 2672014
  • 2 mg | Pharmacode 2672006
  • 5 mg | Pharmacode 2671999

The listing will appear in the Schedule when it is updated for February 2024.

Alternative products

Our clinical advice is that there are funded alternatives for most of the conditions that prazosin is generally prescribed to treat. However, clinical advice has outlined that prazosin is currently a preferred option for people with PTSD. 

We are exploring all options to source an alternate supply of prazosin.

Expected resupply

Unfortunately, the manufacturing plant does not expect to restart production before mid-2025. 

Who to contact

If you take prazosin and have concerns about what this might mean for you, please contact a health professional you trust. Pharmac cannot comment on anyone's individual clinical circumstances. 

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is. 

Sign up to our email list for regular emails about supply issues and more(external link)